Paul Quinlan - Oct 16, 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc. (CBAY)

Role
General Counsel
Signature
/s/ Paul Quinlan
Stock symbol
CBAY
Transactions as of
Oct 16, 2023
Transactions value $
-$54,098
Form type
4
Date filed
10/18/2023, 06:21 PM
Previous filing
Sep 19, 2023
Next filing
Nov 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBAY Common Stock Options Exercise $14.7K +5K $2.94 5K Oct 16, 2023 Direct
transaction CBAY Common Stock Sale -$68.8K -5K -100% $13.76 0 Oct 16, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -5K -3.94% $0.00 122K Oct 16, 2023 Common Stock 5K $2.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.65 to $13.89, inclusive. The reporting person undertakes to provide to CymaBay Therapeutics, Inc., any security holder of CymaBay Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022.